EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis–Associated Lymphoproliferative Disorders

Yoshihiko Hoshida iD, Atsuko Tsujii, Shiro Ohshima, Yukihiko Saeki iD, Masato Yagita, Tomoya Miyamura, Masao Katayama, Tomonori Kawasaki, Yasushi Hiramatsu, Hisaji Oshima, Toshihiko Murayama, Shinji Higa und 48 weitere

Arthritis & Rheumatology · 2024

DOI: 10.1002/art.42809 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Yoshihiko Hoshida und 59 weiteren Autor:innen. Beteiligte Einrichtung: National Health Organization (NHO) Osaka Minami Medical Center, Osaka, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Lymphoproliferative Disorders, Methotrexate. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Clinical Research from the National Hospital Organization, Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In this study, we examine how advancements in novel antirheumatic drugs affect the clinicopathologic features of lymphoproliferative disorder (LPD) in patients with rheumatoid arthritis (RA).

Methods

In this multicenter study across 53 hospitals in Japan, we characterized patients with RA who developed LPDs and visited the hospitals between January 1999 and March 2021. The statistical tools used included Fisher's exact test, the Mann‐Whitney U ‐test, the log‐rank test, logistic regression analysis, and Cox proportional hazards models.

Results

Overall, 752 patients with RA‐associated LPD (RA‐LPD) and 770 with sporadic LPD were included in the study. We observed significant differences in the clinicopathologic features between patients with RA‐LPD and those with sporadic LPD. Histopathological analysis revealed a high frequency of LPD‐associated immunosuppressive conditions. Furthermore, patients with RA‐LPD were evaluated based on the antirheumatic drugs administered. The methotrexate (MTX) plus tacrolimus and MTX plus tumor necrosis factor inhibitor (TNFi) groups had different affected site frequencies and histologic subtypes than the MTX‐only group. Moreover, MTX and TNFi may synergistically affect susceptibility to Epstein‐Barr virus infection. In case of antirheumatic drugs administered after LPD onset, tocilizumab (TCZ)–only therapy was associated with lower frequency of regrowth after spontaneous regression than other regimens.

Conclusion

Antirheumatic drugs administered before LPD onset may influence the clinicopathologic features of RA‐LPD, with patterns changing over time. Furthermore, TCZ‐only regimens are recommended after LPD onset. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsLymphoproliferative DisordersMethotrexateTumor Necrosis Factor InhibitorsHumansMaleFemaleMiddle AgedAgedJapanTacrolimusDrug Therapy, CombinationEpstein-Barr Virus InfectionsAdult

Substanzen

Antirheumatic AgentsMethotrexateTumor Necrosis Factor InhibitorsTacrolimus

Autor:innen und Institutionen

  • National Health Organization (NHO) Osaka Minami Medical Center, Osaka, Japan.
  • Tazuke-Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan.
  • NHO Kyushu Medical Center, Fukuoka, Japan.
  • NHO Nagoya Medical Center, Nagoya, Japan.
  • Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
  • NHO Tokyo Medical Center, Tokyo, Japan.

ORCID-Profile: Yoshihiko Hoshida, Yukihiko Saeki

Förderung

  • Clinical Research from the National Hospital Organization
  • Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research
  • Japan Society for the Promotion of Science

Zitieren

APA

Hoshida, Y., Tsujii, A., Ohshima, S., Saeki, Y., Yagita, M., Miyamura, T., Katayama, M., Kawasaki, T., Hiramatsu, Y., Oshima, H., Murayama, T., Higa, S., Kuraoka, K., Hirano, F., Ichikawa, K., Kurosawa, M., Suzuki, H., Chiba, N., Sugiyama, T., …, & Matsui, K. (2024). Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis–Associated Lymphoproliferative Disorders. Arthritis & Rheumatology. https://doi.org/10.1002/art.42809

Vancouver

Hoshida Y, Tsujii A, Ohshima S, Saeki Y, Yagita M, Miyamura T, et al. Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis–Associated Lymphoproliferative Disorders. Arthritis & Rheumatology. 2024. doi:10.1002/art.42809

BibTeX
@article{Hoshida2024,
  author = {Hoshida, Yoshihiko and Tsujii, Atsuko and Ohshima, Shiro and Saeki, Yukihiko and Yagita, Masato and Miyamura, Tomoya and Katayama, Masao and Kawasaki, Tomonori and Hiramatsu, Yasushi and Oshima, Hisaji and Murayama, Toshihiko and Higa, Shinji and Kuraoka, Kazuya and Hirano, Fuminori and Ichikawa, Kenji and Kurosawa, Mitsutoshi and Suzuki, Hiroaki and Chiba, Noriyuki and Sugiyama, Takao and Minami, Yuko and Niino, Hitoshi and Ihata, Atsushi and Saito, Ikuo and Mitsuo, Akiko and Maejima, Toshitaka and Kawashima, Atsuhiro and Tsutani, Hiroshi and Takahi, Koichiro and Kasai, Takahiko and Shinno, Yoko and Tachiyama, Yoshiro and Teramoto, Norihiro and Taguchi, Kenichi and Naito, Shinji and Yoshizawa, Shigeru and Ito, Masahiro and Suenaga, Yasuo and Mori, Shunsuke and Nagakura, Shoichi and Yoshikawa, Norie and Nomoto, Mitsuharu and Ueda, Atsuhisa and Nagaoka, Shouhei and Tsuura, Yukio and Setoguchi, Keigo and Sugii, Shoji and Abe, Asami and Sugaya, Toshiaki and Sugahara, Hiroyuki and Fujita, Shigeki and Kunugiza, Yasuo and Iizuka, Norishige and Yoshihara, Ryosuke and Yabe, Hiroki and Fujisaki, Tomoaki and Morii, Eiichi and Takeshita, Morishige and Sato, Masakazu and Saito, Kazuyoshi and Matsui, Kiyoshi},
  title = {Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis–Associated Lymphoproliferative Disorders},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  doi = {10.1002/art.42809}
}
Kostenlos starten →